CTOs on the Move

Pattern Bioscience

www.pattern.bio

 
Pattern is building a dream team of scientists and visionaries dedicated to addressing this global problem with faster, smarter diagnostics for more precise treatment.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.pattern.bio
  • 9430 Research Blvd Suite II-340
    Austin, TX USA 78759
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Pattern Bioscience raised $21.9M on 02/05/2020

Similar Companies

xbiotech usa inc

xbiotech usa inc is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Comfort Safety Products

Comfort Safety Products is a Lowell, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Taysha Gene Therapies

Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we hope to rapidly translate our treatments from bench to bedside. We have combined our team`s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for new cures—to dramatically improve patients` lives.

TriSalus Life Sciences

TriSalus Life Sciences is dedicated to improving patient outcomes in pancreatic and other highly intractable solid tumors. TriSalus Infusion Systems, powered by the proprietary Pressure-Enabled Drug Delivery (PEDD) approach with SmartValve technology have the potential to improve the delivery and distribution of diagnostic agents, therapeutics, and immuno-stimulants into the tumor vasculature.

Aeglea

With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.